Targeting Hsp90: small-molecule inhibitors and their clinical development. - Wikidata - awgldk - TriplyDB

Targeting Hsp90: small-molecule inhibitors and their clinical development.

Targeting Hsp90: small-molecule inhibitors and their clinical development.

http://www.wikidata.org/entity/Q37222845

about

Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma Targeting Plasmodium falciparum Hsp90: Towards Reversing Antimalarial Resistance Tumor cell survival pathways activated by photodynamic therapy: a molecular basis for pharmacological inhibition strategies Modulation of α(2C) adrenergic receptor temperature-sensitive trafficking by HSP90 Induction of premature senescence by hsp90 inhibition in small cell lung cancer Assay strategies for the discovery and validation of therapeutics targeting Brugia pahangi Hsp90 Prediction of promiscuous p-glycoprotein inhibition using a novel machine learning scheme Identification, design and bio-evaluation of novel Hsp90 inhibitors by ligand-based virtual screening A purine analog synergizes with chloroquine (CQ) by targeting Plasmodium falciparum Hsp90 (PfHsp90)Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling Connecting gene expression data from connectivity map and in silico target predictions for small molecule mechanism-of-action analysis.Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab To fold or not to fold: modulation and consequences of Hsp90 inhibition.Heat shock protein 90 inhibition by 17-DMAG lessens disease in the MRL/lpr mouse model of systemic lupus erythematosus A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas.Celastrol inhibits Hsp90 chaperoning of steroid receptors by inducing fibrillization of the Co-chaperone p23 Interconnecting molecular pathways in the pathogenesis and drug sensitivity of T-cell acute lymphoblastic leukemia BIIB021, an Hsp90 inhibitor, effectively kills a myelodysplastic syndrome cell line via the activation of caspases and inhibition of PI3K/Akt and NF-κB pathway proteins.Brain-permeable small-molecule inhibitors of Hsp90 prevent alpha-synuclein oligomer formation and rescue alpha-synuclein-induced toxicity.Biological and structural basis for Aha1 regulation of Hsp90 ATPase activity in maintaining proteostasis in the human disease cystic fibrosis.Activating transcription factor-3 (ATF3) functions as a tumor suppressor in colon cancer and is up-regulated upon heat-shock protein 90 (Hsp90) inhibition White matter loss in a mouse model of periventricular leukomalacia is rescued by trophic factors The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer.Heat shock protein 90 in neurodegenerative diseases Heat shock protein 90β stabilizes focal adhesion kinase and enhances cell migration and invasion in breast cancer cells Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin Angiogenesis inhibitors: current strategies and future prospects.Comparative analysis of novel and conventional Hsp90 inhibitors on HIF activity and angiogenic potential in clear cell renal cell carcinoma: implications for clinical evaluation Protein folding in the cytoplasm and the heat shock response.Modulation of melanoma cell phospholipid metabolism in response to heat shock protein 90 inhibition.BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy Induced protein degradation: an emerging drug discovery paradigm.Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic Hsp90 inhibitor BIIB021 enhances triptolide-induced apoptosis of human T-cell acute lymphoblastic leukemia cells in vitro mainly by disrupting p53-MDM2 balance Direct effects of non-antifungal agents used in cancer chemotherapy and organ transplantation on the development and virulence of Candida and Aspergillus species Synthesis of purine-scaffold fluorescent probes for heat shock protein 90 with use in flow cytometry and fluorescence microscopy.Progesterone receptor chaperone complex-based high-throughput screening assay: identification of capsaicin as an inhibitor of the Hsp90 machine.The human immunodeficiency virus protease inhibitor ritonavir is potentially active against urological malignancies.Small-molecule proteostasis regulators for protein conformational diseases.

P2860

Q24607424-E62620A2-BD36-4777-BA4A-F81EDCE9AAA9 Q26864290-5D336E20-25A1-46BB-BECC-D9FF0FC9C83F Q28085631-DC1CC60B-8F3A-48A2-80AA-77EF0BE9FF2C Q28390844-CBFC32C3-416B-4746-9FFA-9E795B54EA17 Q28474354-6F692F4A-8F86-4A75-914A-7A2A55AF7600 Q28474428-9FA966A4-AF1B-4FA7-AF51-D703BEA13F64 Q28481547-35A40EB9-3A9E-444D-8FBD-731A7D4E9461 Q28485925-06E23C14-59CF-4163-9B79-41182EB9DD20 Q28533944-45903247-33D0-4848-A61F-CF956BD9DB85 Q28741023-0C956729-7F9F-4D20-A611-DF833F3A63CF Q30855130-D8DE3DE1-95FE-4CCF-94F1-D99CEC47CECA Q33527397-B756A3AA-D16B-41F9-988E-0F211CEBD43A Q33531705-CE056707-183E-4506-A36C-7268B71404B5 Q33577386-8DF58A39-C1FC-4618-BE54-8727689DB180 Q33588432-7E025E9F-EB87-45EA-9344-95BDBC91008C Q33662410-BA483481-6962-4F83-ACD5-4454CE4860D3 Q33706334-61E7E064-F9C4-40F3-9B23-E575AE1EA76D Q33706374-0FB479BC-9A14-4D84-B33C-0A629900F21D Q33714875-0920A2BE-089A-4C12-9FA4-367BA203E0C9 Q33721206-6DC7033E-024B-48CC-9019-8A563095A361 Q33762700-698D0139-EBB3-43EB-9C0E-52C115EE909B Q33772241-69E910E3-9E85-4C69-9742-BF69C14F4B7D Q33912171-7458C28D-33C1-48EE-B9AA-60B217B614A5 Q33961301-4978765C-A78F-4A20-80D0-6E7D49878A6E Q33998634-CD6EC404-BD2A-48C4-9747-A78FA29A4159 Q34018372-0E15087D-88CA-4B6D-9EEE-8D03718FB93C Q34056376-19707E31-1E28-49F4-B3B5-B3AEBBC46F5C Q34102029-8ABE06BE-0827-4304-95C4-2B82C219B05D Q34152827-6883F0E2-7213-4FF5-A993-1E91C0E757CD Q34249948-F83E81B9-D268-4B5F-B327-D05C13C67104 Q34360164-8F9026C9-19B1-4937-B81B-BECBD9904CD7 Q34545841-91AF08A2-9BBC-40F1-B9F2-BD1B62557AAC Q34568868-3CEFDC82-5C37-4453-9535-300C759253CE Q34817365-6056EE89-7F44-4924-957E-5CDEE655911D Q35044980-BEAB8ED9-4D8D-491F-B53B-ADEC36FA9982 Q35214605-35EBE036-29C4-45DB-B9D8-337D5BBC8040 Q35219926-AB0C3AC6-1DA7-4661-A1AC-1020F795ACFB Q35237464-284A52DA-75B0-4097-A2A4-F36CB8A3EBA4 Q35444159-B9D7E890-62D0-4979-8719-5567E3B3D8C0 Q35683088-0EE1DA29-0371-48A3-822D-61733FD26B57

P2860

Targeting Hsp90: small-molecule inhibitors and their clinical development.

http://www.wikidata.org/entity/Q37222845

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 31 July 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Targeting Hsp90: small-molecule inhibitors and their clinical development.

@en

Targeting Hsp90: small-molecule inhibitors and their clinical development.

@nl

type

label

Targeting Hsp90: small-molecule inhibitors and their clinical development.

@en

Targeting Hsp90: small-molecule inhibitors and their clinical development.

@nl

prefLabel

Targeting Hsp90: small-molecule inhibitors and their clinical development.

@en

Targeting Hsp90: small-molecule inhibitors and their clinical development.

@nl

P1433

Q37222845-3A9C3E8D-28BA-4E5F-A79D-4343007271A7

P1476

Q37222845-D4251460-1D2D-46E2-93BF-3B490F79DABC

P2093

Q37222845-3D0B382B-6DF3-4D49-898C-E8A8875A43D6

Q37222845-7CA05477-B31A-46AB-8133-1FDC7F7B53BC

Q37222845-BC7EE0E1-F858-4DB6-93C3-D357A86D5B61

P2860

Q37222845-062B13B2-69FF-48A6-A76E-4E2A9CF4DC32

Q37222845-06D963DF-8242-47D2-A227-9A5E8B987929

Q37222845-10A2EC14-5DCB-40B8-BFD5-65C41BE9FED9

Q37222845-29DEB582-3856-475E-8D32-7089AFA8E070

Q37222845-389A0A9D-6E43-491B-823D-F241B80F3677

Q37222845-4C3B192C-5819-4C3E-95FC-F75CF848848C

Q37222845-6F6BACED-84B1-4974-A5B3-540E6730E273

Q37222845-7A5CED55-6923-4AB9-85F8-14EABE5EEE2F

Q37222845-89C83CD6-CCE5-470B-94FA-BBF065850B97

Q37222845-8A2CB546-3678-4DA3-98CE-AD2BA62D2326

P304

Q37222845-BEFD9214-D330-4FB8-A47A-0DDE7C03A578

P31

Q37222845-22E36D8C-724A-4625-A3D9-39C79C7A82B2

P356

Q37222845-BAB4C019-EE23-4B01-A9E0-102E40003B9E

P433

Q37222845-475BB0F6-A851-4DFB-A8C5-8FCB7BF02A78

P478

Q37222845-643D5824-DFFF-484A-B680-9B172A83B474

P50

Q37222845-09080B1F-14A7-42A4-893C-54F4B01BD034

P577

Q37222845-F938C51F-845C-4949-8EE1-440FD68BEE50

P5875

Q37222845-7BB093E3-54C4-44D6-A804-2CFEEC115BC9

P698

Q37222845-DAB66D5E-8324-433D-9A30-07972B77DC56

P921

Q37222845-E6A01CBF-34A7-4B56-A148-102BE598344F

P932

Q37222845-65490414-D98F-4D1A-B2EF-A09F2D9F74A9

P356

J.COPH.2008.06.015

P1433

Current Opinion in Pharmacology

P1476

Targeting Hsp90: small-molecule inhibitors and their clinical development.

@en

P2093

Alexander Gozman

http://www.w3.org/2001/XMLSchema#string

Ronnie Maharaj

http://www.w3.org/2001/XMLSchema#string

Tony Taldone

http://www.w3.org/2001/XMLSchema#string

P2860

BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors.

Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamy

NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis

Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress

HSP90 and the chaperoning of cancer

Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.

Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.

Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.

The stress response: implications for the clinical development of hsp90 inhibitors.

The achilles heel of ErbB-2/HER2: regulation by the Hsp90 chaperone machine and potential for pharmacological intervention.

P304

370-374

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.COPH.2008.06.015

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Gabriela Chiosis

P577

2008-07-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51418213

http://www.w3.org/2001/XMLSchema#string

P698

18644253

http://www.w3.org/2001/XMLSchema#string

P921

retaspimycin hydrochloride

P932

2760289

http://www.w3.org/2001/XMLSchema#string